© 2022 MJH Life Sciences and Modern Retina. All rights reserved.
© 2022 MJH Life Sciences™ and Modern Retina. All rights reserved.
May 23, 2022
Professor Anat Loewenstein, MD, discusses data regarding the efficacy of faricimab at targeting both the VEGF and Ang2 pathways in patients with neovascular AMD and diabetic macular edema.
May 20, 2022
An end-of-week review of retina news and stories from May 13 to May 20.
May 10, 2022
According to the company, the trial did not demonstrate efficacy on the key clinical endpoints. As a result, Oxurion will now shift its focus to the Phase 2 development program for THR-149, which recently demonstrated a compelling safety and efficacy profile for the treatment of DME.
May 07, 2022
The data presented at ARVO showed single subcutaneous doses of D-4517.2 were safe, well-tolerated in healthy subjects.
April 11, 2022
The trial will study the effect of the drug in treatment-naïve patients with diabetic macular edema (DME) who are members of underrepresented patient populations, ie, Black, Hispanic, Latin American, and Indigenous people.
April 08, 2022
Investigators found that patients with neovascular age-related macular degeneration in all countries included in the study lost vision as a result of the lockdown and reduced number of treatments during the COVID-19 pandemic.
April 07, 2022
Approval is based on year 1 data from the Phase III KESTREL and KITE trials investigating brolucizumab 6 mg versus aflibercept 2 mg in DME patients.
April 06, 2022
A University of Houston study found that minorities have fewer eye exams, higher instances of disease.
April 01, 2022
Bausch + Lomb and Clearside Biomedical Inc. are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis.
February 24, 2022
Alimera Sciences, Inc. announces statistically significant improvements in best corrected visual acuity, central subfield thickness and treatment burden for patients with diabetic macular edema.